Repurposing existing drugs to inhibit SARS-CoV-2 infection in airway epithelial cells(AECs)is a quick way to find novel treatments for COVID-19.Computational screening has found dicoumarol(DCM),a natural anticoagulant...Repurposing existing drugs to inhibit SARS-CoV-2 infection in airway epithelial cells(AECs)is a quick way to find novel treatments for COVID-19.Computational screening has found dicoumarol(DCM),a natural anticoagulant,to be a potential SARS-CoV-2 inhibitor,but its inhibitory effects and possible working mechanisms remain unknown.Using air-liquid interface culture of primary human AECs.展开更多
基金The authors would like to thank the study participants who donated their samples for the advancement of scientific knowledge.The authors would also like to thank Dr.Jennie Wong(from the Medical and Scientific Communication,Research Support Unit,Yong Loo Lin School of Medicine,National University of Singapore,Singapore)for assistance in the language editing of this manuscript.This work was supported by The National High-Level Talents Program(X.X.T.),Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program(2017BT01S155)Guangzhou Institute of Respiratory Health Open Project(X.X.T.)+2 种基金the Postdoctoral Science Foundation of China(2022M710897,Y.P.)the Postdoctoral Startup Foundation of Guangzhou City(Y.P.)Zhongnanshan Medical Foundation of Guangdong Province(ZNSA-2020013,Z.Q.Z.).
文摘Repurposing existing drugs to inhibit SARS-CoV-2 infection in airway epithelial cells(AECs)is a quick way to find novel treatments for COVID-19.Computational screening has found dicoumarol(DCM),a natural anticoagulant,to be a potential SARS-CoV-2 inhibitor,but its inhibitory effects and possible working mechanisms remain unknown.Using air-liquid interface culture of primary human AECs.
